Moreover, mechanistic studies are needed to fully elucidate how TIGIT-mediated signaling pathways suppress NK cell function in DLBCL, potentially uncovering new therapeutic targets and refine existing strategies. Here, TIGIT is linked to diffuse large B-cell lymphoma.